BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...15,  vTv said the Elevage study of azeliragon...
...for developing Alzheimer’s, and the idea that azeliragon...
...conditions was based on the observations that azeliragon’s...
BioCentury | Dec 16, 2020
Deals

Dec. 15 Quick Takes: Singlera raises $150M for cancer dx; plus AnGes-Emendo, Entresto, vTv and Unity

...drug.vTv misses endpoint in Alzheimer’s-diabetes studyvTv Therapeutics Inc. (NASDAQ:VTVT) said the Phase II Elevage study of azeliragon...
...O’Neill, CMO and EVP of R&D of Sarepta Therapeutics Inc. (NASDAQ:SRPT). Jeff Cranmer Entresto, sacubitril/valsartan (LCZ696) azeliragon (TTP488, PF-04494700, PF-4494700) Singlera AnGes Emendo...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...other indications. (A) Last year, vTv Therapeutics Inc. (NASDAQ:VTVT) halted two Phase III trials of azeliragon...
...ALS, AD Ph Ib Other Receptor for advanced glycation endproducts (RAGE) vTv Therapeutics Inc. (NASDAQ:VTVT) Azeliragon...
BioCentury | Jun 15, 2018
Clinical News

vTv to propose path forward for AD candidate despite Phase III miss

...vTv Therapeutics Inc. (NASDAQ:VTVT) said azeliragon (TTP488) missed the co-primary endpoints compared with placebo in Part...
...Part B, azeliragon missed the co-primary endpoints in a prespecified subgroup of patients with maximal azeliragon...
...Daily Living Inventory (ADCS-ADL) Status: Additional Phase III data Milestone: NA Jaime De Leon azeliragon (TTP488, PF-04494700, PF-4494700) vTv...
BioCentury | Apr 13, 2018
Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

...vTv Therapeutics Inc. (NASDAQ:VTVT) said it will discontinue clinical trials of azeliragon (TTP488) after the Alzheimer’s...
...once-daily 5 mg oral azeliragon or placebo for 18 months. On Part A's co-primary endpoints, azeliragon...
...Study-Activities of Daily Living Inventory (ADCS-ADL) Status: Phase III discontinued Milestone: NA Brian Moy azeliragon (TTP488, PF-04494700, PF-4494700) vTv...
BioCentury | Apr 9, 2018
Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

...vTv Therapeutics Inc. (NASDAQ:VTVT) said it will discontinue clinical trials of azeliragon (TTP488) after the Alzheimer’s...
...once-daily 5 mg oral azeliragon or placebo for 18 months. On Part A's co-primary endpoints, azeliragon...
...glucokinase (GCK; GK) activator. vTv was off $0.16 to $3.26 on Monday. Brian Moy azeliragon (TTP488, PF-04494700, PF-4494700) vTv...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...NASDAQ:VTL) ELAD system Acute liver failure Ph III VTL-308 data 3Q18 vTv Therapeutics Inc. (NASDAQ:VTVT) Azeliragon...
BioCentury | Jun 9, 2017
Clinical News

vTv completes enrollment in Phase III of RAGE antagonist for AD

...about 800 patients with mild Alzheimer’s disease in the Phase III STEADFAST trial of azeliragon (TTP488...
...of Daily Living Inventory (ADCS-ADL). vTv plans to report data from the trial next year. Azeliragon...
...advanced glycation endproducts (RAGE) antagonist. vTv Therapeutics LLC (NASDAQ:VTVT), High Point, N.C. Product: Azeliragon ( TTP488...
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Receptor for advanced glycation endproducts (RAGE)

...the model. vTv Therapeutics Inc. has the RAGE antagonist azeliragon ( TTP488 ; PF-04494700 ; PF-4494700...
BioCentury | Aug 1, 2016
Clinical News

Azeliragon: Additional Phase IIb data

...trial in 399 patients with mild to moderate AD showed that once-daily 5 mg oral azeliragon...
...trial (see BioCentury, Nov. 12, 2012). Top-line data from the Phase III STEADFAST trial of azeliragon...
...late 2017 or early 2018. vTv Therapeutics Inc. (NASDAQ:VTVT), High Point, N.C. Product: Azeliragon ( TTP488...
Items per page:
1 - 10 of 21